Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide

Open access
Lee, Chanju, Jeong, Hyunju, Bae, Younghyeon, Shin, Kyungmoon, Kang, Sinwoo, Kim, Hwikyung, Oh, Jayoung, Bae, Hyunsu · 2019 · Journal for ImmunoTherapy of Cancer

Abstract

Background Tumor-associated macrophages (TAMs) are the major component of tumor-infiltrating immune cells. Macrophages are broadly categorized as M1 or M2 types, and TAMs have been shown to express an M2-like phenotype. TAMs promote tumor progression and contribute to resistance to chemotherapies. Therefore, M2-like TAMs are potential targets for the cancer immunotherapy. In this study, we targeted M2-like TAMs using a hybrid peptide, MEL-dKLA, composed of melittin (MEL), which binds preferentially to M2-like TAMs, and the pro-apoptotic peptide d (KLAKLAK)2 (dKLA), which induces mitochondrial death after cell membrane penetration. Methods The M1 or M2-differentiated RAW264.7 cells were used for mitochondrial colocalization and apoptosis test in vitro. For in vivo study, the murine Lewis lung carcinoma cells were inoculated subcutaneously in the right flank of mouse. The dKLA, MEL and MEL-dKLA peptides were intraperitoneally injected at 175 nmol/kg every 3 days. Flow cytometry analysis of tumor-associated macrophages and immunofluorescence staining were performed to investigate the immunotherapeutic effects of MEL-dKLA. Results We showed that MEL-dKLA induced selective cell death of M2 macrophages in vitro, whereas MEL did not disrupt the mitochondrial membrane. We also showed that MEL-dKLA selectively targeted M2-like TAMs without affecting other leukocytes, such as T cells and dendritic cells, in vivo. These features resulted in lower tumor growth rates, tumor weights, and angiogenesis in vivo. Importantly, although both MEL and MEL-dKLA reduced numbers of CD206+ M2-like TAMs in tumors, only MEL-dKLA induced apoptosis in CD206+ M2-like TAMs, and MEL did not induce cell death. Conclusion Taken together, our study demonstrated that MEL-dKLA could be used to target M2-like TAMs as a promising cancer therapeutic agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-019-0610-4

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Selective cytotoxicity of MEL-dKLA in M2-differentiated RAW264.7 macrophages. (a, b) Effects of dKLA, MEL, or MEL-dKLA on cell viability after incubation for 24 h. After incubation, cell viability was measured with MTS assays. The percent cell viability was standardized based on the absorbance of the PBS-treated control. *P < 0.05, **P < 0.01, ***P < 0.001 versus the dKLA group; #P < 0.05, ##P < 0.01, ###P < 0.001 versus the MEL group. (c) Cell cycle analysis revealed by propidium iodide (PI) staining. All results are expressed as means ± SEMs. (d, e) Annexin V-FITC and MitoTracker-Red CMXRos staining were measured by flow cytometry in (d) M1- and (e) M2-differentiated RAW264.7 macrophages. The cells were treated with PBS or 0.8 μM peptides. Each population of MitoTrackerlow Annexin V+ cells was normalized to the population treated with PBS as a control. *P < 0.05, **P < 0.01 versus the PBS group; ##P < 0.01 versus the dKLA group; $P < 0.05, $$P < 0.01 versus the MEL group. (n = 3)
Fig. 1 Selective cytotoxicity of MEL-dKLA in M2-differentiated RAW264.7 macrophages. (a, b) Effects of dKLA, MEL, or MEL-dKLA on cell viability after incubation for 24 h. After incubation, cell viability was measured with MTS assays. The percent cell viability was standardized based on the absorbance of the PBS-treated control. *P < 0.05, **P < 0.01, ***P < 0.001 versus the dKLA group; #P < 0.05, ##P < 0.01, ###P < 0.001 versus the MEL group. (c) Cell cycle analysis revealed by propidium iodide (PI) staining. All results are expressed as means ± SEMs. (d, e) Annexin V-FITC and MitoTracker-Red CMXRos staining were measured by flow cytometry in (d) M1- and (e) M2-differentiated RAW264.7 macrophages. The cells were treated with PBS or 0.8 μM peptides. Each population of MitoTrackerlow Annexin V+ cells was normalized to the population treated with PBS as a control. *P < 0.05, **P < 0.01 versus the PBS group; ##P < 0.01 versus the dKLA group; $P < 0.05, $$P < 0.01 versus the MEL group. (n = 3)CC BY · PubMed Central
Fig. 2 Induction of cell death due to mitochondrial membrane disruption. (a, b) Cellular respiration (a) and glycolysis (b) of peptide-treated cells were analyzed in real time with an XF24 flux analyzer. Oligomycin, FCCP, and Rot/AA were injected into XF24 plates sequentially after the baseline measurement. The y-axis shows the OCRs or ECARs, and the x-axis indicates the measurement number. (c–e) Basal respiration (c), ATP production (d), and maximal respiration (e) were compared between the experimental and PBS-treated control groups. (f-h) The cell energy phenotype, OCRs, and ECARs under basal and stressed conditions. All values are means ± SEMs (n = 3). *P < 0.05, **P < 0.01 versus the PBS group; #P < 0.05, versus the dKLA group; $P < 0.05 versus the MEL group (n = 3)
Fig. 2 Induction of cell death due to mitochondrial membrane disruption. (a, b) Cellular respiration (a) and glycolysis (b) of peptide-treated cells were analyzed in real time with an XF24 flux analyzer. Oligomycin, FCCP, and Rot/AA were injected into XF24 plates sequentially after the baseline measurement. The y-axis shows the OCRs or ECARs, and the x-axis indicates the measurement number. (c–e) Basal respiration (c), ATP production (d), and maximal respiration (e) were compared between the experimental and PBS-treated control groups. (f-h) The cell energy phenotype, OCRs, and ECARs under basal and stressed conditions. All values are means ± SEMs (n = 3). *P < 0.05, **P < 0.01 versus the PBS group; #P < 0.05, versus the dKLA group; $P < 0.05 versus the MEL group (n = 3)CC BY · PubMed Central
Fig. 3 Colocalization of MEL-dKLA with mitochondria in vitro. (a) Representative images of mitochondria (green), peptides (red), and DAPI (blue) are shown. (b) Correlation coefficients were measured by Pearson’s statistics. Values ranged from − 1 to + 1, representing full negative or positive correlations. Zero indicates no correlation between the two colors. Results are expressed as means ± SEMs; ***P < 0.001. Scale bar, 20 μm (n = 3)
Fig. 3 Colocalization of MEL-dKLA with mitochondria in vitro. (a) Representative images of mitochondria (green), peptides (red), and DAPI (blue) are shown. (b) Correlation coefficients were measured by Pearson’s statistics. Values ranged from − 1 to + 1, representing full negative or positive correlations. Zero indicates no correlation between the two colors. Results are expressed as means ± SEMs; ***P < 0.001. Scale bar, 20 μm (n = 3)CC BY · PubMed Central
Fig. 4 Antitumor activities of MEL and MEL-dKLA in vivo. (a) Tumor size, (b) tumor weight, (c) tumor size fold change, (d) and body weight were measured. Tumor-bearing mice were treated with each peptide every 3 days (for a total of three times) starting on day 5 after tumor inoculation. Tumor fold change was calculated based on the tumor size of the last day normalized to the initiation of tumor growth on day 5 (n = 5). (e) Immunofluorescence staining of endothelial cells in subcutaneously implanted LLC tumor paraffin sections. (f) Vessel density was quantified as integrated density per area (μm2) by Image J. Total magnification, 630×. Scale bar, 50 μm. (n = 6). All data are presented as means ± SEMs; *P < 0.05, **P < 0.01, ***P < 0.0001 versus the PBS group; #P < 0.05, ##P < 0.01, ###P < 0.0001 versus the dKLA group
Fig. 4 Antitumor activities of MEL and MEL-dKLA in vivo. (a) Tumor size, (b) tumor weight, (c) tumor size fold change, (d) and body weight were measured. Tumor-bearing mice were treated with each peptide every 3 days (for a total of three times) starting on day 5 after tumor inoculation. Tumor fold change was calculated based on the tumor size of the last day normalized to the initiation of tumor growth on day 5 (n = 5). (e) Immunofluorescence staining of endothelial cells in subcutaneously implanted LLC tumor paraffin sections. (f) Vessel density was quantified as integrated density per area (μm2) by Image J. Total magnification, 630×. Scale bar, 50 μm. (n = 6). All data are presented as means ± SEMs; *P < 0.05, **P < 0.01, ***P < 0.0001 versus the PBS group; #P < 0.05, ##P < 0.01, ###P < 0.0001 versus the dKLA groupCC BY · PubMed Central
Fig. 5 Selective reduction of the M2-like TAM population by MEL and MEL-dKLA. (a) M1-like macrophages that infiltrated into the tumor stroma were stained as CD45+F4/80+CD86+ (upper panel) and M2-like TAMs were marked as CD45+F4/80+CD206+ (bottom panel). The cells are shown as dot plots within the F4/80 and CD86 or CD206 axis gated on CD45+ cells from total live-gated cells. (b, c) Data for each cell phenotype are displayed as the percentages of M1- and M2-like TAMs in CD45+ cells (left panel) and the exact number of M1- and M2-like TAMs counted per 104 total single cells (right panel). (d) The M1/M2 ratio was calculated based on the percentage of F4/80+CD86+ cells and F4/80+CD206+ cells in CD45+ cells (left panel) or using the counted population in total sing cells (right panel). (e, f) The number of tissue-resident M1 or M2 macrophages were counted per 104 total single cells. (g) CD4 T cells (CD45+CD4+CD8−), (h) regulatory T cells (CD4+CD25+Foxp3+), (i) CD8 T cells (CD45+CD4−CD8+), and (j) dendritic cells (CD45+CD11b+CD11c+) were detected within total live-gated cells. All values are presented as means ± SEMs (n = 5); *P < 0.05, **P < 0.01, ***P < 0.0001 versus the PBS group; #P < 0.05, ##P < 0.01 versus the dKLA group; and $P < 0.05 versus the MEL group (n = 5)
Fig. 5 Selective reduction of the M2-like TAM population by MEL and MEL-dKLA. (a) M1-like macrophages that infiltrated into the tumor stroma were stained as CD45+F4/80+CD86+ (upper panel) and M2-like TAMs were marked as CD45+F4/80+CD206+ (bottom panel). The cells are shown as dot plots within the F4/80 and CD86 or CD206 axis gated on CD45+ cells from total live-gated cells. (b, c) Data for each cell phenotype are displayed as the percentages of M1- and M2-like TAMs in CD45+ cells (left panel) and the exact number of M1- and M2-like TAMs counted per 104 total single cells (right panel). (d) The M1/M2 ratio was calculated based on the percentage of F4/80+CD86+ cells and F4/80+CD206+ cells in CD45+ cells (left panel) or using the counted population in total sing cells (right panel). (e, f) The number of tissue-resident M1 or M2 macrophages were counted per 104 total single cells. (g) CD4 T cells (CD45+CD4+CD8−), (h) regulatory T cells (CD4+CD25+Foxp3+), (i) CD8 T cells (CD45+CD4−CD8+), and (j) dendritic cells (CD45+CD11b+CD11c+) were detected within total live-gated cells. All values are presented as means ± SEMs (n = 5); *P < 0.05, **P < 0.01, ***P < 0.0001 versus the PBS group; #P < 0.05, ##P < 0.01 versus the dKLA group; and $P < 0.05 versus the MEL group (n = 5)CC BY · PubMed Central
Fig. 6 Selective cell death of M2-like TAMs by MEL-dKLA in the tumor stroma. (a) The representative histograms of Annexin+ cells in F4/80+CD86+ M1 macrophages or (b) F4/80+CD206+ M2 macrophages were normalized to maximum peak and displayed as half offset histograms. (c) The percentages of Annexin V+ cells in M1 or M2 macrophages are shown in a bar graph. **P < 0.01 versus the PBS group, ##P < 0.01 versus the dKLA group, $$P < 0.01 versus the MEL group, &&&P < 0.0001 versus the M1 group (n = 6)
Fig. 6 Selective cell death of M2-like TAMs by MEL-dKLA in the tumor stroma. (a) The representative histograms of Annexin+ cells in F4/80+CD86+ M1 macrophages or (b) F4/80+CD206+ M2 macrophages were normalized to maximum peak and displayed as half offset histograms. (c) The percentages of Annexin V+ cells in M1 or M2 macrophages are shown in a bar graph. **P < 0.01 versus the PBS group, ##P < 0.01 versus the dKLA group, $$P < 0.01 versus the MEL group, &&&P < 0.0001 versus the M1 group (n = 6)CC BY · PubMed Central
Fig. 7 Antitumor effect of MEL-dKLA in an orthotopic model of lung cancer. (a) Representative images showing the lungs of wild mice (WT) and LLC tumor-inoculated mice treated with 175 nmol/kg of each peptide every 3 days. Drugs were administered 5 days after tumor injection into the left lung. Tumors are marked with black arrows. Size bar, 1 cm. (b) Representative H&E-stained histologic sections of the paraffin-embedded left lung. Magnification, × 1.5; size bar, 1 mm. Percentage of tumor area was calculated as tumor area per total area by Image J (left bottom panel). (c) Tumor size and (d) weight of left lung were measured at the end of the experiment on day 16. *P < 0.05, **P < 0.01 versus the PBS group; #P < 0.05, ##P < 0.01 versus the dKLA group; $$P < 0.01 versus the MEL group (n = 7 per group; WT n = 4)
Fig. 7 Antitumor effect of MEL-dKLA in an orthotopic model of lung cancer. (a) Representative images showing the lungs of wild mice (WT) and LLC tumor-inoculated mice treated with 175 nmol/kg of each peptide every 3 days. Drugs were administered 5 days after tumor injection into the left lung. Tumors are marked with black arrows. Size bar, 1 cm. (b) Representative H&E-stained histologic sections of the paraffin-embedded left lung. Magnification, × 1.5; size bar, 1 mm. Percentage of tumor area was calculated as tumor area per total area by Image J (left bottom panel). (c) Tumor size and (d) weight of left lung were measured at the end of the experiment on day 16. *P < 0.05, **P < 0.01 versus the PBS group; #P < 0.05, ##P < 0.01 versus the dKLA group; $$P < 0.01 versus the MEL group (n = 7 per group; WT n = 4)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 211

Metadata

Authors
Lee, C., Jeong, H., Bae, Y., Shin, K., Kang, S., Kim, H., Oh, J., & Bae, H.
Affiliations
Kyung Hee University (KR)
Corresponding author
Bae, Hyunsu
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2019-06-07
Volume
7
Issue
1
Pages
147-147
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2948475148
Cited by
211
References
52
Citations by year
2026: 3 · 2025: 18 · 2024: 34 · 2023: 32 · 2022: 35 · 2021: 38 · 2020: 48 · 2019: 3
FWCI
12.36
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Research Foundation of Korea (2017R1A2B3009574, 2017M3A9E4057926)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Pharmacology (medical) › Healthcare and Venom Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
tumor-associated macrophages, M2 macrophages, melittin, proapoptotic peptide, hybrid peptides, CD206, mitochondrial apoptosis, Lewis lung carcinoma, cancer immunotherapy, tumor growth inhibition, angiogenesis, RAW 264.7 macrophages
MeSH terms
Animals, Flow Cytometry, Humans, Immunotherapy, Macrophages, Melitten, Peptides, Apoptosis, Carcinoma, Lewis Lung, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. https://app.cochat.ai/papers/10.1186/s40425-019-0610-4
The paper
Lee, C., Jeong, H., Bae, Y., Shin, K., Kang, S., Kim, H., Oh, J., & Bae, H. (2019). Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-019-0610-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.